Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Industry Must Take Phase IV “Seriously,” Commissioner Tells PhRMA

Executive Summary

Pharmaceutical manufacturers need to step up their commitment to postmarketing surveillance and studies, FDA Commissioner McClellan told the Pharmaceutical Research & Manufacturers of America March 28 in Naples, Fla

You may also be interested in...



Phase IV Reporting Improves In Year After FDA Issues Challenge To PhRMA

The pharmaceutical industry appears to be doing a significantly better job in filing Phase IV study updates in a timely fashion, FDA's postmarketing database shows

Phase IV Reporting Improves In Year After FDA Issues Challenge To PhRMA

The pharmaceutical industry appears to be doing a significantly better job in filing Phase IV study updates in a timely fashion, FDA's postmarketing database shows

FDA Minds DTC “Reminder Ad” Increase, Seeks Better “Brief Summaries”

FDA is concerned that industry may be using "reminder ads" more frequently as a way to avoid including risk information in direct-to-consumer marketing

Related Content

UsernamePublicRestriction

Register

PS041540

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel